Cas-CLOVER™ – the clean alternative to CRISPR/Cas9 for gene editing in drug discovery and development
Key Points Cas-CLOVER is a cleaner gene editing alternative to [...]
OncoRat® featured in Clinical Cancer Research for prostate cancer studies
Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems: A case [...]
The OncoRat® is the ideal host for patient-derived xenografts of ovarian cancer cells
Ovarian cancer is the most lethal gynecological cancer in the [...]
Evolution of the rat model
Rats have been favored for drug development studies because the [...]
H358 NSCLC xenografts in humanized rats: the ideal in vivo model for studying KRAS mutations
Lung adenocarcinomas, the major histological subtype of non-small cell lung [...]
Hera Biolabs announces Molecular Cancer Therapeutics publication on immunodeficient rats for oncology research
Hera Biolabs, the University of Michigan, Case Western Reverse University [...]
Breakthroughs in gene editing allows for the creation of superior preclinical oncology models
Gene editing is getting a lot of attention in the [...]
The OncoRat®: Hosting valuable tumor xenograft models that are difficult or impossible to study using in vitro or mouse models
One of the most widely used methods of modeling human [...]
Patient derived xenograft studies from wider varieties of patient sub-populations promise improved clinical trial selection and design
Around 85% of preclinical drugs entering clinical trials in oncology [...]
OncoRat® PDX models highlighted in Drug Discovery News (DDN) Special Report on Cancer: Aiming for Avatars
While advances in in-vitro platforms have allowed researchers to better [...]